Nigel C. Jones

Nigel C. Jones

PhD, Bachelor’s (Honours)

Neurologist

25+ years Experience

📍 Melbourne

About of Nigel C. Jones

Nigel C. Jones is a neurologist based on Commercial Road in Melbourne, VIC 3004.


Neurology can cover a lot of different problems that affect the brain, nerves, and how the body moves. Nigel works with people dealing with seizures and seizure disorders, including epilepsy and different seizure patterns. This can include absence seizures, and generalised tonic-clonic seizures. At times, care is also needed for conditions that come after a head injury, such as post-traumatic epilepsy, along with other effects from traumatic brain injury.


There’s also help for movement and nerve conditions. That can mean looking after people with Parkinson’s disease, focal dystonia, and other movement disorders. Some patients come in with memory concerns, dementia, or ongoing memory loss where brain changes may play a role. Others may be managing symptoms where medication effects are part of the story, such as drug-induced dyskinesia.


Nigel also sees people with brain-related conditions that are present from early life. These can include rare epilepsy syndromes and developmental brain differences. Each case is worked through step by step, because the right plan depends on what’s happening, not just the name on a referral.


With over 25 years of experience, Nigel brings a steady, practical approach to care. Neurological symptoms can be stressful, and things often change over time. In many cases, the goal is to understand what’s driving the symptoms and then help patients make clear decisions about next steps, whether that’s review of current treatment, safety advice, or planning further checks.


Education is anchored in Monash University. Nigel has a PhD and also holds Bachelor’s (Honours) qualifications from Monash. That research background helps in how complex cases are thought through, especially when symptoms don’t fit neatly into a simple pattern.


Research and learning don’t stop after training. Nigel has a history of publishing work in the medical space, and that helps keep knowledge up to date as new evidence and treatment options come through.


Clinical trials aren’t always the right path, but the discussion around options stays open when they might fit a person’s situation.

Education

  • PhD — Monash University
  • Bachelor’s (Honours) — Monash University
  • Bachelor’s — Monash University

Services & Conditions Treated

EpilepsyPost-Traumatic EpilepsyAbsence SeizureEpilepsy Juvenile AbsenceGeneralized Tonic-Clonic SeizureSeizuresAlzheimer's DiseaseSchizophreniaTraumatic Brain InjuryArrhythmiasDehydrationDementiaDrug Induced DyskinesiaDupuytren ContractureEncephalitisFibromatosisFocal DystoniaHyperventilationHypothalamic HamartomasLissencephalyLissencephaly 1Memory LossMiller-Dieker SyndromeMosaicismMovement DisordersParkinson's DiseaseRestrictive Cardiomyopathy (RCM)Status EpilepticusSturge-Weber SyndromeSubcortical Band HeterotopiaTorticollis

Publications

5 total
Effect of ceftriaxone on the glutamate-glutamine cycle and seizure susceptibility of Tg2576 mouse model of Alzheimer's disease.

Journal of Alzheimer's disease : JAD • November 05, 2024

Hattapark Dejakaisaya, Runxuan Lin, Anna Harutyunyan, Jianxiong Chan, Patrick Kwan, Nigel Jones

Effects of NMDA receptor antagonists on working memory and gamma oscillations, and the mediating role of the GluN2D subunit.

Neuropsychopharmacology : Official Publication Of The American College Of Neuropsychopharmacology • January 02, 2025

Chitra Vinnakota, Matthew Hudson, Kazutaka Ikeda, Soichiro Ide, Masayoshi Mishina, Suresh Sundram, Nigel Jones, Rachel Hill

Working memory relies on synchronised network oscillations involving complex interplay between pyramidal cells and GABAergic interneurons. NMDA receptor (NMDAR) antagonists influence both network oscillations and working memory, but the relationship between these two consequences has not been elucidated. This study aimed to determine the effect of NMDAR antagonists on network oscillations during a working memory task in mice, and the contribution of the GluN2D receptor subunit. After training wildtype (WT) and GluN2D-knockout (KO) mice on the Trial-Unique-Non-match to Location (TUNL) touchscreen task of working memory, recording electrodes were implanted into the prefrontal cortex (PFC) and hippocampus. Mice were challenged with either (S)-ketamine (30 mg/kg), (R)-ketamine (30 mg/kg), phencyclidine (PCP, 1 mg/kg), MK-801 (0.3 mg/kg) or saline prior to TUNL testing while simultaneous local field potential recordings were acquired. PCP disrupted working memory accuracy in WT (p = 0.001) but not GluN2D-KO mice (p = 0.79). MK-801 (p < 0.0001), (S)-ketamine (p < 0.0001) and (R)-ketamine (p = 0.007) disrupted working memory accuracy in both genotypes. PCP increased baseline hippocampal gamma (30-80 Hz) power in WT (p = 0.0015) but not GluN2D-KO mice (p = 0.92). All drugs increased baseline gamma power in the PFC in both genotypes (p < 0.05). Low gamma was induced during the maintenance phase of the TUNL task and increased when mice correctly completed the task (p = 0.024). This response-dependent increase in low gamma was disrupted by all drugs. In summary, PCP action involves the GluN2D subunit of the NMDA receptor in the hippocampus to alter baseline gamma power and working memory. Task-induced low gamma activity during maintenance aligns with task performance, and is disrupted by all NMDAR antagonists.

A pre-existing chronic Toxoplasma gondii infection promotes epileptogenesis and neuropathology in a mouse model of mesial temporal lobe epilepsy.

Brain, Behavior, And Immunity • October 09, 2024

Objective: There is initial evidence that the common neurotropic parasite Toxoplasma gondii is a risk factor for the development of epilepsy; however, whether it influences epileptogenesis is unknown. This study investigated whether a pre-existing chronic T. gondii infection alters epileptogenesis and neuropathology in a mouse model of mesial temporal lobe epilepsy. Methods: Male and female C57BL/6Jax mice were intraperitoneally administered T. gondii tachyzoites or vehicle control. After 6 weeks, mice underwent self-sustained electrical status epilepticus (SSSE) through an implanted bipolar electrode, or a sham procedure. Continuous video-EEG recordings were taken 0-4- and 12-16-weeks post-SSSE to detect spontaneous seizures. Neuroinflammatory markers were assessed within 1-week post-SSSE, behavior testing was done at 8-12 weeks post-SSSE, and ex vivo MRI was conducted at 16 weeks post-SSSE. Results: Male T. gondii + SSSE mice had an increased incidence of epilepsy compared to Vehicle + SSSE, while female T. gondii + SSSE mice had worse seizure severity compared to non-infected SSSE mice. There was amplified neuroinflammation in both male and female T. gondii + SSSE mice compared to Vehicle + SSSE mice. T. gondii infection in the absence of SSSE also resulted in epilepsy and neuroinflammation. MRI revealed abnormalities in brain morphology in T. gondii + SSSE male and female mice and changes in white matter integrity in male T. gondii + SSSE mice, compared to both non-infected SSSE and T. gondii control mice. SSSE and T. gondii infection impacted anxiety and spatial memory in males, and anxiety and social behavior in females. Conclusions: These findings demonstrate that a chronic T. gondii infection can result in epilepsy, and that a pre-existing T. gondii infection exacerbates epileptogenesis following a brain insult, in mice.

Ligand-receptor interactions: A key to understanding microglia and astrocyte roles in epilepsy.

Epilepsy & Behavior : E&B • August 14, 2024

Peravina Thergarajan, Terence O'brien, Nigel Jones, Idrish Ali

Epilepsy continues to pose significant social and economic challenges on a global scale. Existing therapeutic approaches predominantly revolve around neurocentric mechanisms, and fail to control seizures in approximately one-third of patients. This underscores the pressing need for novel and complementary treatment approaches to address this gap. An increasing body of literature points to a role for glial cells, including microglia and astrocytes, in the pathogenesis of epilepsy. Notably, microglial cells, which serve as pivotal inflammatory mediators within the epileptic brain, have received increasing attention over recent years. These immune cells react to epileptogenic insults, regulate neuronal processes, and play diverse roles during the process of epilepsy development. Additionally, astrocytes, another integral non-neuronal brain cells, have garnered increasing recognition for their dynamic contributions to the pathophysiology of epilepsy. Their complex interactions with neurons and other glial cells involve modulating synaptic activity and neuronal excitability, thereby influencing the aberrant networks formed during epileptogenesis. This review explores the alterations in microglial and astrocytic function and their mechanisms of communication following an epileptogenic insult, examining their contribution to epilepsy development. By comprehensively studying these mechanisms, potential avenues could emerge for refining therapeutic strategies and ameliorating the impact of this complex neurological disease.

Plasma microRNAs as prognostic biomarkers for development of severe epilepsy after experimental traumatic brain injury-EpiBioS4Rx Project 1 study.

Epilepsia • August 02, 2024

Mette Heiskanen, Xavier Ndode Ekane, Idrish Ali, Cesar Santana Gomez, Noora Puhakka, Shalini Gupta, Pedro Andrade, Riikka Immonen, Pablo Casillas Espinosa, Eppu Manninen, Gregory Smith, Rhys Brady, Juliana Silva, Emma Braine, Matt Hudson, Glen Yamakawa, Nigel Jones, Sandy Shultz, Neil Harris, David Wright, Olli Gröhn, Richard Staba, Terence O'brien, Asla Pitkänen

Objective: To test a hypothesis that acutely regulated plasma microRNAs (miRNAs) can serve as prognostic biomarkers for the development of post-traumatic epilepsy (PTE). Methods: Adult male Sprague-Dawley rats (n = 245) were randomized to lateral fluid-percussion-induced traumatic brain injury (TBI) or sham operation at three study sites (Finland, Australia, United States). Video-electroencephalography (vEEG) was performed on the seventh post-injury month to detect spontaneous seizures. Tail vein plasma collected 48 h after TBI for miRNA analysis was available from 209 vEEG monitored animals (45 sham, 164 TBI [32 with epilepsy]). Based on small RNA sequencing and previous data, the seven most promising brain enriched miRNAs (miR-183-5p, miR-323-3p, miR-434-3p, miR-9a-3p, miR-124-3p, miR-132-3p, and miR-212-3p) were validated by droplet digital polymerase chain reaction (ddPCR). Results: All seven plasma miRNAs differentiated between TBI and sham-operated rats. None of the seven miRNAs differentiated TBI rats that did and did not develop epilepsy (p > .05), or rats with ≥3 vs <3 seizures in a month (p > .05). However, miR-212-3p differentiated rats that developed epilepsy with seizure clusters (i.e., ≥3 seizures within 24 h) from those without seizure clusters (.34 ± .14 vs .60 ± .34, adj. p < .05) with an area under the curve (AUC) of .81 (95% confidence interval [CI] .65-.97, p < .01, 64% sensitivity, 95% specificity). Lack of elevation in miR-212-3p also differentiated rats that developed epilepsy with seizure clusters from all other TBI rats (n = 146, .34 ± .14 vs .55 ± .31, p < .01) with an AUC of .74 (95% CI .61-.87, p < .01, 82% sensitivity, 62% specificity). Glmnet analysis identified a combination of miR-212-3p and miR-132-3p as an optimal set to differentiate TBI rats with vs without seizure clusters (cross-validated AUC .75, 95% CI .47-.92, p < .05). Conclusions: miR-212-3p alone or in combination with miR-132-3p shows promise as a translational prognostic biomarker for the development of severe PTE with seizure clusters.

Frequently Asked Questions

What services does Dr Nigel C. Jones offer?
Epilepsy, Post-Traumatic Epilepsy, Absence Seizure, Epilepsy Juvenile Absence, Generalized Tonic-Clonic Seizure, Seizures, Alzheimer's Disease, Schizophrenia, Traumatic Brain Injury, and various movement and neurological conditions such as Parkinson's Disease, Dystonia, Encephalitis, and more.
What conditions does he treat as a neurologist?
He treats epilepsy-related conditions, memory and cognitive issues like memory loss and dementia, movement disorders, Parkinson’s disease, traumatic brain injury, and other neurological conditions listed in his services.
How many years of experience does Dr Jones have?
Over 25 years of experience.
Where is his practice located?
His practice is in Melbourne, at Commercial Road, Melbourne, VIC 3004, Australia.
What should I expect when booking an appointment?
Appointments are arranged through his Melbourne practice. Details on booking are provided by the clinic.
What are some common concerns patients have that this doctor can help with?
Patients often seek help for epilepsy and seizures, memory problems and dementia, movement disorders, and other neurological conditions listed in his services.